New Strategies, Targets in Triple-Negative Breast Cancer

In this video, Stacy Moulder, MD, of MD Anderson Cancer Center, highlights efforts to identify various subtypes and molecular targets in triple-negative breast cancer, an often difficult-to-treat disease, which could potentially lead to treatment options already approved by the US Food and Drug Administration.

Dr. Moulder also discusses the challenge in finding patients with triple-negative disease that will have durable responses to chemotherapy, and the need for better molecular diagnostic assays to identify those patients who will be resistant to cytotoxic agents.